Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs

Obesity rates are increasing worldwide and there is a need for novel therapeutic treatment options. The endocannabinoid system has been linked to homeostatic processes, including metabolism, food intake, and the regulation of body weight. Rimonabant, an inverse agonist for the cannabinoid CB1 recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Thomas, Le Foll, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356944/
https://www.ncbi.nlm.nih.gov/pubmed/32512776
http://dx.doi.org/10.3390/biom10060855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356944/
https://www.ncbi.nlm.nih.gov/pubmed/32512776
http://dx.doi.org/10.3390/biom10060855

Ejemplares similares